The latest EW stock price forecast points to a moderate upside, with analysts eyeing a target range of $92–$97 over the next quarter, driven by stable revenue growth and strong demand in the medical devices segment. Trading volume has shown consistent institutional interest, which often signals a healthy technical setup. 22% = US$1.4b ÷ US$6.4b (Based on the trailing twelve months to June 2023). Edwards Lifesciences currently carries a Zacks Rank #3 (Hold). Traders eyeing EW note that options market activity has skewed toward calls, signaling growing bullish speculation. This sentiment reinforces the positive stock price forecast for the next earnings cycle.
